Skip to Content

Annexin Pharmaceuticals AB - Stock Quote ANNX

Rating as of

Morningstar's Annexin Pharmaceuticals AB Stock Analysis

Valuation
Currency in SEK
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics - ANNX

Annexin Pharmaceuticals AB's Company Profile

Business Description

Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.

Contact
Norrtullsgatan 6
Stockholm, SE-113 29, Sweden
T +46 709651665
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2019
Stock Type
Employees 5